The state of the hunt:

The European Union and India made new moves to curtail vaccine exports.
  COVAX warned of delivery delays.
  Pfizer and BioNTech launched a pediatric trial of their vaccine in children as young as 6 months.



Approved or authorized vaccines
New data, new questions for AstraZeneca: If AstraZeneca thought higher-than-expected efficacy results this week from the U.S.-based Phase 3 trial of AZD1222 would…

The state of the hunt: 

AstraZeneca inked a $1 billion deal Thursday with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop and manufacture Oxford University’s recombinant adenovirus vaccine candidate. CanSino’s recombinant shot was found “tolerable and immunogenic” 28 days post-vaccination, according to a preliminary Phase 1 assessment published in The Lancet. Moderna announced positive interim Phase 1 data for its mRNA vaccine.


Britain’s government announced on Sunday $160 million in new funding and a faster construction timeline for its Vaccines Manufacturing and Innovation Centre (VMIC), which will now come online a year early, in summer 2021. The nonprofit facility—founded by Oxford University, Imperial College London and the London School of Hygiene & Tropical Medicine—will also see a twentyfold expansion in planned production capacity, to 70 million vaccine doses within six months of opening.